Expiration date: 08/2026

Pharmacological action

An immunosuppressant. The effect of Rapamun is due to the suppression of T-cell activation by blocking Ca2+-mediated and Ca2+-independent intracellular signal transmission, binding to a specific cytosolic protein - immunophilin. Reduces the activity of T- and B-lymphocytes and suppresses the rejection of allogeneic graft.

Indications

Prevention of graft rejection (in adult patients with low and moderate immunological risk after kidney transplantation, in combination with GCS and cyclosporine).

Contraindications

Pregnancy, lactation, childhood and adolescence, hypersensitivity to sirolimus.

Special instructions

Therapy should be carried out by a doctor with relevant experience in transplantology.

Composition

1 tablet contains sirolimus 1 mg

Method of administration and dosage

Rapamun is taken orally. It is recommended to use in combination with GCS and cyclosporine for 2-3 months. Maintenance therapy, if necessary, can be continued in combination with GCS without cyclosporine.

Initial therapy (for 2-3 months after transplantation): a saturating dose of 6 mg once for 48 hours after transplantation, then a maintenance dose of 2 mg / day. In the future, the dose should be selected so that the Cmin in the blood is within 4-12 ng / ml (chromatographic method). The cmin of cyclosporine in the blood during the first 2-3 months after transplantation should be maintained at the level of 150-400 ng/ml (monoclonal concentration determination method).